Stockscreener 앱 받기
29.32
5.01%
1.40
시간 외 거래:
29.11
-0.21
-0.72%
전일 마감가:
$27.92
열려 있는:
$27.71
하루 거래량:
12.21M
Relative Volume:
1.30
시가총액:
$6.84B
수익:
$2.35B
순이익/손실:
$128.37M
주가수익비율:
56.16
EPS:
0.5221
순현금흐름:
$57.42M
1주 성능:
+0.38%
1개월 성능:
+1.88%
6개월 성능:
+5.05%
1년 성능:
-37.78%
1일 변동 폭
$27.60
$29.80
1주일 범위
$27.22
$29.80
52주 변동 폭
$13.74
$50.19
Hims Hers Health Inc Stock (HIMS) Company Profile
명칭
Hims Hers Health Inc
전화
415-851-0195
주소
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
29.32 | 6.84B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
20.15 | 64.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.97 | 46.62B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.00 | 43.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
77.80 | 32.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
586.48 | 25.15B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-11 | 재개 | JP Morgan | Neutral |
| 2026-05-12 | 재확인 | Needham | Buy |
| 2026-04-24 | 개시 | JP Morgan | Overweight |
| 2026-03-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2026-03-10 | 업그레이드 | Citigroup | Sell → Neutral |
| 2026-03-09 | 업그레이드 | Needham | Hold → Buy |
| 2026-02-24 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2026-01-12 | 개시 | Evercore ISI | In-line |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-21 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-04 | 재확인 | Needham | Buy |
| 2025-04-29 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2025-01-07 | 개시 | BTIG Research | Buy |
| 2024-12-17 | 개시 | Morgan Stanley | Overweight |
| 2024-11-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-08-22 | 개시 | Needham | Buy |
| 2024-08-09 | 다운그레이드 | Imperial Capital | Outperform → In-line |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-04-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-10 | 개시 | Canaccord Genuity | Buy |
| 2024-02-28 | 업그레이드 | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2023-12-07 | 개시 | Imperial Capital | In-line |
| 2023-07-28 | 개시 | TD Cowen | Outperform |
| 2023-04-11 | 개시 | Robert W. Baird | Neutral |
| 2023-02-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-08 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-07-15 | 개시 | SVB Leerink | Underperform |
| 2022-04-14 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | Deutsche Bank | Hold |
| 2021-12-02 | 개시 | Jefferies | Hold |
| 2021-11-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 개시 | BofA Securities | Neutral |
| 2021-05-20 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 개시 | Truist | Hold |
| 2021-03-09 | 개시 | Credit Suisse | Neutral |
| 2021-03-02 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-02-17 | 개시 | Citigroup | Neutral |
| 2021-02-12 | 개시 | Piper Sandler | Neutral |
| 2021-02-08 | 개시 | Tigress Financial | Buy |
모두보기
Hims Hers Health Inc 주식(HIMS)의 최신 뉴스
What Are Hims & Hers Health Stock Investors Overlooking? - Trefis
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Deadline Alert: Hims & Hers Health, Inc. Investors Have - GlobeNewswire
HIMS 1-WEEK DEADLINE ALERT: Hims & Hers Health Investors with Significant Losses Encouraged to Contact Hagens Berman Before Nov. 2, 2026 Deadline in Securities Class Action - PR Newswire
INV DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Innventure, Inc. Investors to Secure Counsel Before Important October 27 Deadline in Securities Class ActionINV - GlobeNewswire Inc.
FTK DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Flotek Industries, Inc. Investors to Secure Counsel Before Important October 26 Deadline in Securities Class ActionFTK - GlobeNewswire Inc.
HIMS FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.
Hims & Hers Health (HIMS) Alert: Securities Class Action Pending, Investors with Losses Encouraged to Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline - GlobeNewswire Inc.
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Millrose Properties, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionMRP - GlobeNewswire Inc.
Hims & Hers Health Inc (HIMS) Stock Down 4.9% -- Now Undervalued? GF Score: 75/100 - GuruFocus
Hims & Hers Health, Inc. (HIMS) Declines More Than Market: Some Information for Investors - Yahoo Finance
Hims & Hers Health, Inc. (HIMS) Declines More Than Market: Some Information for Investors - Zacks Investment Research
Hims & Hers Defends Subscription Practices And Privacy Disclosures Against Lawsuit - Benzinga
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - Carroll County Mirror-Democrat
Hims & Hers Health, Inc. Tokenized Stock (Coinbase) price today, HIMSc to USD live price, marketcap and chart - CoinMarketCap
Hims & Hers Health (HIMS) Facing Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower - The National Law Review
Hims Seeks Dismissal of FTC Suit Over User Data, Subscriptions - Bloomberg.com
Hims & Hers Health, Inc. (HIMS) Stock Forecasts - Yahoo Finance
A New Era for Testosterone Care: Hims Launches New Injectable and Oral TRT Options - Hims & Hers Newsroom
Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men’s Health Launch to Date - HIMS investor relations
Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock DeclineInvestors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Reminds Hims & Hers Health, Inc. Investors of the Upcoming Lead Plaintiff Deadline and Urges Investors to Contact the Firm Before November 2nd - GlobeNewswire Inc.
Hims & Hers Health Inc (HIMS) Shares Surge 3.8% -- What GF Score of 75 Tells Investors - GuruFocus
Hims & Hers Gains as It Launches Men’s Weight-Loss Care in Germany - Yahoo Finance
Hims & Hers Health Jumps 6.2% Amid Sector-Wide Rally - AlphaStreet
What's Next for Hims & Hers Health, Inc. Shareholders After 14.73% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline - Morningstar
Hims & Hers gains after German launch - Seeking Alpha
Hims & Hers Health launches online weight management service for men in Germany - Reuters
Hims & Hers Health launches online weight management service for men in Germany - Yahoo Finance Singapore
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Hims Is Reaching the Three Million Member Milestone - The Motley Fool
HIMS DEADLINE: ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.
What Are Hims & Hers Health Stock Bears Missing? - Trefis
Hims & Hers Health: The Lollapalooza Effect Of GLP-1s (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health Inc (HIMS) Stock Down 4.5% -- Now Undervalued? GF Score: 75/100 - GuruFocus
ROSEN, LEADING INVESTOR COUNSEL, Encourages Millrose Properties, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionMRP - GlobeNewswire Inc.
HIMS DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.
What Does Hims & Hers Health (HIMS) Expansion Into The UK And Australia Mean? - Yahoo Finance
Hims & Hers Health (HIMS) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline - PR Newswire
How Is Hims & Hers Health, Inc. (NYSE:HIMS) Reshaping Its Business? - Kalkine Media
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Killeen Daily Herald
Kaplan Fox & Kilsheimer LLP Encourages Hims & Hers Health, Inc - The National Law Review
Hims & Hers Health rises as HHS moves ahead with plan for compounding peptides - Seeking Alpha
US FDA takes step to change peptide compounding policy - Reuters
Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Our Commitment to Independent, Clinician-Led Care - Hims & Hers Newsroom
Hims Hers Health Inc (HIMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Hims Hers Health Inc 주식 (HIMS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Boughton Soleil | Officer |
Oct 14 '26 |
Proposed Sale |
29.06 |
3,461 |
100,577 |
0 |
| Okupe Oluyemi | Chief Financial Officer |
Oct 01 '26 |
Sale |
29.70 |
2,000 |
59,400 |
234,527 |
| Okupe Oluyemi | Officer |
Oct 01 '26 |
Proposed Sale |
29.70 |
2,000 |
59,400 |
0 |
| Boughton Soleil | Chief Legal Officer |
Sep 30 '26 |
Sale |
29.17 |
3,461 |
100,957 |
300,809 |
| Boughton Soleil | Officer |
Sep 30 '26 |
Proposed Sale |
29.17 |
3,461 |
100,957 |
0 |
| Okupe Oluyemi | Chief Financial Officer |
Sep 22 '26 |
Option Exercise |
5.01 |
14,000 |
70,140 |
265,804 |
| Okupe Oluyemi | Officer |
Sep 22 '26 |
Proposed Sale |
29.95 |
29,277 |
876,846 |
0 |
| Okupe Oluyemi | Chief Financial Officer |
Sep 22 '26 |
Sale |
29.95 |
29,277 |
876,846 |
236,527 |
| Okupe Oluyemi | Chief Financial Officer |
Sep 17 '26 |
Sale |
28.82 |
12,313 |
354,861 |
251,804 |
| Okupe Oluyemi | Officer |
Sep 17 '26 |
Proposed Sale |
28.82 |
12,313 |
354,861 |
0 |
0.05%
6.70%
자본화:
|
볼륨(24시간):